SKF-91488

SKF-91488 is a drug used in scientific research, which acts as a selective antagonist for the D1 dopamine receptor.^[1] It has been used in the study of Parkinson's disease and other medical conditions where dopamine function is impaired.

Pharmacology[edit]

SKF-91488 is a selective antagonist for the D1 dopamine receptor. This means it binds to this receptor and blocks its activation by dopamine. This can be useful in research to understand the role of the D1 receptor in various physiological processes and diseases.

Uses in Research[edit]

SKF-91488 has been used in research to study the role of the D1 receptor in various conditions. For example, it has been used in studies of Parkinson's disease, a condition characterized by the death of dopamine-producing cells in the brain. By blocking the D1 receptor, researchers can study the effects of reduced dopamine activity on the symptoms of this disease.

Side Effects[edit]

As with any drug, SKF-91488 can have side effects. These can include nausea, vomiting, and other gastrointestinal symptoms. However, because it is used primarily in research rather than in clinical practice, these side effects are typically managed in a controlled laboratory setting.

References[edit]

↑ "SKF 91488, a selective D1 dopamine receptor antagonist".European Journal of Pharmacology.April 1984;86(3–4)
241–50.doi:10.1016/0014-2999(84)90368-3.PMID:6326961.

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

SKF-91488

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] "SKF 91488, a selective D1 dopamine receptor antagonist".European Journal of Pharmacology.April 1984;86(3–4)
241–50.doi:10.1016/0014-2999(84)90368-3.PMID:6326961.

[1]